PD-L1 gene amplification and focality: relationship with protein expression

被引:5
|
作者
Jardim, Denis Leonardo [1 ]
Murugesan, Karthikeyan [2 ,3 ]
Elvin, Julia A. [3 ]
Huang, Richard S. P. [3 ]
Kurzrock, Razelle [4 ,5 ]
机构
[1] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil
[2] Fdn Med Inc, Canc Genom Res, Cambridge, MA USA
[3] Fdn Med Inc, Cambridge, MA USA
[4] WIN Consortium Personalized Canc Therapy, Dept Med, San Diego, CA USA
[5] Med Coll Wisconsin, Milwaukee, WI USA
关键词
Biomarkers; Tumor; Genetic Markers; Immunohistochemistry;
D O I
10.1136/jitc-2022-006311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PD-L1 (CD274) amplification occurs in a small subset of malignancies and may predict anti-PD-1/PD-L1 immunotherapy responsiveness. We hypothesized that both copy number (CN) and focality of cancer-related PD-L1 amplifications impact protein expression, and, thus, analyzed solid tumors that underwent comprehensive genomic profiling between March 2016 and February 2022 at Foundation Medicine. PD-L1 CN alterations were detected using a comparative genomic hybridization-like method. PD-L1 CN changes were correlated with PD-L1 protein expression (DAKO 22C3 antibody) by immunohistochemistry (IHC). Overall, 60,793 samples were analyzed (most frequent histologies: lung adenocarcinoma (20%), colon adenocarcinoma (12%), lung squamous carcinoma (8%)). Using a definition of CD274 CN >= specimen ploidy +4 (6 copies), 1.21% of tumors (738/60,793) were PD-L1 amplified. Focality category distribution was as follows: <0.1 mB (n=18 (2.4%)), >= 0.1 to <4 mB (n=230 (31.1%)), >= 4 to <20 mB (n=310 (42%)), >= 20mB (n=180 (24.4%)). Lower levels of PD-L1 amplification (below specimen ploidy +4) were more frequently non-focal amplifications compared to higher levels. In addition, more focal amplification (<0.1 mB) correlated with higher PD-L1 IHC expression. Median tumor proportion score (TPS) for samples with PD-L1 amplification (ploidy >=+4) according to focality were 87.5% (<0.1 mB), 80% (>= 0.1 to <4 mB), 40% (>= 4 to <20 mB), 1% (>= 20mB). In specimens with PD-L1 ploidy less than +4, but highly focal (<0.1 mB), the 75th percentile of PD-L1 expression by TPS was 80%. Conversely, non-focal (>= 20 mB) PD-L1 amplification (ploidy >=+4) can present high PD-L1 expression (TPS >= 50%), albeit infrequently (0.09% of our cohort). In conclusion, PD-L1 expression measured by IHC is influenced by PD-L1 amplification level and focality. Further correlation between amplification, focality, protein expression and therapeutic outcome for PD-L1 and other targetable genes warrants exploration.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] PD-L1 Protein Expression and PD-L1 Gene Amplification in Breast Cancer
    Voronel, Olga
    Dalvi, Siddhartha
    Kallakury, Bhaskar Vs
    Sheehan, Christine E.
    Boguniewicz, Ann B.
    Ross, Jeffrey S.
    LABORATORY INVESTIGATION, 2016, 96 : 77A - 77A
  • [2] PD-L1 Protein Expression and PD-L1 Gene Amplification in Breast Cancer
    Voronel, Olga
    Dalvi, Siddhartha
    Kallakury, Bhaskar V. S.
    Sheehan, Christine E.
    Boguniewicz, Ann B.
    Ross, Jeffrey S.
    MODERN PATHOLOGY, 2016, 29 : 77A - 77A
  • [3] PD-L1 Protein Expression and PD-L1 Gene Amplification in Urothelial Carcinoma of the Urinary Bladder
    Zuo, Chunlai
    Kallakury, Bhaskar V. S.
    Firestone, Bryan
    Voronel, Olga
    Sheehan, Christine E.
    Nazeer, Tipu
    Ross, Jeffrey S.
    MODERN PATHOLOGY, 2016, 29 : 272A - 272A
  • [4] PD-L1 Protein Expression and PD-L1 Gene Amplification in Urothelial Carcinoma of the Urinary Bladder
    Zuo, Chunlai
    Kallakury, Bhaskar V. S.
    Firestone, Bryan
    Voronel, Olga
    Sheehan, Christine E.
    Nazeer, Tipu
    Ross, Jeffrey S.
    LABORATORY INVESTIGATION, 2016, 96 : 272A - 272A
  • [5] Infrequent PD-L1 Protein Expression and Gene Amplification in Prostatic Adenocarcinomas (PACs)
    Najjar, Saleh N.
    Kallakury, Bhaskar V. S.
    Sheehan, Christine E.
    Nazeer, Tipu
    Ross, Jeffrey
    LABORATORY INVESTIGATION, 2017, 97 : 246A - 246A
  • [6] Infrequent PD-L1 Protein Expression and Gene Amplification in Prostatic Adenocarcinomas (PACs)
    Najjar, Saleh N.
    Kallakury, Bhaskar V. S.
    Sheehan, Christine E.
    Nazeer, Tipu
    Ross, Jeffrey
    MODERN PATHOLOGY, 2017, 30 : 246A - 246A
  • [7] CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
    Straub, Melanie
    Drecoll, Enken
    Pfarr, Nicole
    Weichert, Wilko
    Langer, Rupert
    Hapfelmeier, Alexander
    Goetz, Carolin
    Wolff, Klaus-Dietrich
    Kolk, Andreas
    Specht, Katja
    ONCOTARGET, 2016, 7 (11) : 12024 - 12034
  • [8] PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements
    Manso, Rebeca
    Rodriguez-Perales, Sandra
    Torres-Ruiz, Raul
    Santonja, Carlos
    Rodriguez-Pinilla, Socorro-Maria
    LEUKEMIA & LYMPHOMA, 2021, 62 (07) : 1648 - 1656
  • [9] PD-L1 Protein Expression and Gene Amplification Correlate with the Clinicopathological Characteristics and Prognosis of Lung Squamous Cell Carcinoma
    Chen, Zhenwen
    Zhao, Ning
    Wang, Qi
    Xi, Yanfeng
    Tian, Xiaoai
    Wu, Huiwen
    Xu, Yirong
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 6365 - 6375
  • [10] Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.
    Kucharczyk, T.
    Grenda, A.
    Krawczyk, P.
    Nicos, M.
    Jarosz, B.
    Szumilo, J.
    Reszka, K.
    Trojanowski, T.
    Milanowski, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S732 - S732